Endocrine tumours of the stomach

Gianfranco Delle Fave, Gabriele Capurso, Massimo Milione, Francesco Panzuto

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Gastric endocrine tumours (gastric carcinoids) usually grow from enterochromaffin-like (ECL) cells. Three types of tumour may be distinguished on the basis of the background gastric pathology: type I, which develops in atrophic body gastritis (ABG); type II, which is associated with multiple endocrine neoplasia and Zollinger-Ellison syndrome; and the sporadic type III, which is not associated with any background pathology. This classification plays a major role in determining the optimal approach to these diseases. In fact, type I carcinoids can be considered to be benign lesions, with exceptional risk of metastases. Type II, in contrast, may be associated with distant metastases, which are also common in type III carcinoids. The therapeutic approach is based mainly on endoscopic excision and somatostatin analogues in types I and II, or on surgical resection in type III. Both types I and II grow under the stimulus of hypergastrinaemia through a well-described sequence. However, gastrin is sufficient to cause ECL cell hyperplasia and dysplasia, but not transformation, which is due to menin defects in MEN-I patients, or to other unknown alterations in ABG. Several other candidates-including Bcl2, p53 and MMP9-have been linked with carcinoid initiation and progression. The biology of type III tumours which are not associated with hypergastrinaemia is still poorly understood.

Original languageEnglish
Pages (from-to)659-673
Number of pages15
JournalBailliere's Best Practice and Research in Clinical Gastroenterology
Volume19
Issue number5 SPEC. ISS.
DOIs
Publication statusPublished - Oct 2005

Fingerprint

Carcinoid Tumor
Stomach
Enterochromaffin-like Cells
Atrophic Gastritis
Neoplasms
Pathology
Multiple Endocrine Neoplasia
Neoplasm Metastasis
Zollinger-Ellison Syndrome
Multiple Endocrine Neoplasia Type 1
Gastrins
Somatostatin
Hyperplasia
Therapeutics

Keywords

  • Atrophic body gastritis
  • Gastric carcinoids
  • Gastric endocrine tumours
  • Hypergastrinaemia
  • Multiple endocrine neoplasia type I
  • Zollinger-Ellison syndrome

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Endocrine tumours of the stomach. / Delle Fave, Gianfranco; Capurso, Gabriele; Milione, Massimo; Panzuto, Francesco.

In: Bailliere's Best Practice and Research in Clinical Gastroenterology, Vol. 19, No. 5 SPEC. ISS., 10.2005, p. 659-673.

Research output: Contribution to journalArticle

Delle Fave, Gianfranco ; Capurso, Gabriele ; Milione, Massimo ; Panzuto, Francesco. / Endocrine tumours of the stomach. In: Bailliere's Best Practice and Research in Clinical Gastroenterology. 2005 ; Vol. 19, No. 5 SPEC. ISS. pp. 659-673.
@article{493f970f758446da815363011fb9bb68,
title = "Endocrine tumours of the stomach",
abstract = "Gastric endocrine tumours (gastric carcinoids) usually grow from enterochromaffin-like (ECL) cells. Three types of tumour may be distinguished on the basis of the background gastric pathology: type I, which develops in atrophic body gastritis (ABG); type II, which is associated with multiple endocrine neoplasia and Zollinger-Ellison syndrome; and the sporadic type III, which is not associated with any background pathology. This classification plays a major role in determining the optimal approach to these diseases. In fact, type I carcinoids can be considered to be benign lesions, with exceptional risk of metastases. Type II, in contrast, may be associated with distant metastases, which are also common in type III carcinoids. The therapeutic approach is based mainly on endoscopic excision and somatostatin analogues in types I and II, or on surgical resection in type III. Both types I and II grow under the stimulus of hypergastrinaemia through a well-described sequence. However, gastrin is sufficient to cause ECL cell hyperplasia and dysplasia, but not transformation, which is due to menin defects in MEN-I patients, or to other unknown alterations in ABG. Several other candidates-including Bcl2, p53 and MMP9-have been linked with carcinoid initiation and progression. The biology of type III tumours which are not associated with hypergastrinaemia is still poorly understood.",
keywords = "Atrophic body gastritis, Gastric carcinoids, Gastric endocrine tumours, Hypergastrinaemia, Multiple endocrine neoplasia type I, Zollinger-Ellison syndrome",
author = "{Delle Fave}, Gianfranco and Gabriele Capurso and Massimo Milione and Francesco Panzuto",
year = "2005",
month = "10",
doi = "10.1016/j.bpg.2005.05.002",
language = "English",
volume = "19",
pages = "659--673",
journal = "Bailliere's Best Practice and Research in Clinical Gastroenterology",
issn = "1521-6918",
publisher = "Bailliere Tindall Ltd",
number = "5 SPEC. ISS.",

}

TY - JOUR

T1 - Endocrine tumours of the stomach

AU - Delle Fave, Gianfranco

AU - Capurso, Gabriele

AU - Milione, Massimo

AU - Panzuto, Francesco

PY - 2005/10

Y1 - 2005/10

N2 - Gastric endocrine tumours (gastric carcinoids) usually grow from enterochromaffin-like (ECL) cells. Three types of tumour may be distinguished on the basis of the background gastric pathology: type I, which develops in atrophic body gastritis (ABG); type II, which is associated with multiple endocrine neoplasia and Zollinger-Ellison syndrome; and the sporadic type III, which is not associated with any background pathology. This classification plays a major role in determining the optimal approach to these diseases. In fact, type I carcinoids can be considered to be benign lesions, with exceptional risk of metastases. Type II, in contrast, may be associated with distant metastases, which are also common in type III carcinoids. The therapeutic approach is based mainly on endoscopic excision and somatostatin analogues in types I and II, or on surgical resection in type III. Both types I and II grow under the stimulus of hypergastrinaemia through a well-described sequence. However, gastrin is sufficient to cause ECL cell hyperplasia and dysplasia, but not transformation, which is due to menin defects in MEN-I patients, or to other unknown alterations in ABG. Several other candidates-including Bcl2, p53 and MMP9-have been linked with carcinoid initiation and progression. The biology of type III tumours which are not associated with hypergastrinaemia is still poorly understood.

AB - Gastric endocrine tumours (gastric carcinoids) usually grow from enterochromaffin-like (ECL) cells. Three types of tumour may be distinguished on the basis of the background gastric pathology: type I, which develops in atrophic body gastritis (ABG); type II, which is associated with multiple endocrine neoplasia and Zollinger-Ellison syndrome; and the sporadic type III, which is not associated with any background pathology. This classification plays a major role in determining the optimal approach to these diseases. In fact, type I carcinoids can be considered to be benign lesions, with exceptional risk of metastases. Type II, in contrast, may be associated with distant metastases, which are also common in type III carcinoids. The therapeutic approach is based mainly on endoscopic excision and somatostatin analogues in types I and II, or on surgical resection in type III. Both types I and II grow under the stimulus of hypergastrinaemia through a well-described sequence. However, gastrin is sufficient to cause ECL cell hyperplasia and dysplasia, but not transformation, which is due to menin defects in MEN-I patients, or to other unknown alterations in ABG. Several other candidates-including Bcl2, p53 and MMP9-have been linked with carcinoid initiation and progression. The biology of type III tumours which are not associated with hypergastrinaemia is still poorly understood.

KW - Atrophic body gastritis

KW - Gastric carcinoids

KW - Gastric endocrine tumours

KW - Hypergastrinaemia

KW - Multiple endocrine neoplasia type I

KW - Zollinger-Ellison syndrome

UR - http://www.scopus.com/inward/record.url?scp=27744450644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744450644&partnerID=8YFLogxK

U2 - 10.1016/j.bpg.2005.05.002

DO - 10.1016/j.bpg.2005.05.002

M3 - Article

C2 - 16253892

AN - SCOPUS:27744450644

VL - 19

SP - 659

EP - 673

JO - Bailliere's Best Practice and Research in Clinical Gastroenterology

JF - Bailliere's Best Practice and Research in Clinical Gastroenterology

SN - 1521-6918

IS - 5 SPEC. ISS.

ER -